Korro Bio, Inc.: KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...
Korro Bio gets Orphan Drug Designation from FDA for its genetic disorder treatment
Korro Bio received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat Alpha-1 Antitrypsin ...
Korro Bio's KRRO-110 Gets FDA Orphan Drug Designation
Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...
Korro Bio receives ODD from U.S. FDA for AATD
Korro Bio (KRRO) announced that the U.S. Food and Drug Administration has granted orphan drug designation, ODD, to the investigational medicine ...
The Manila Times3d
Global Uranium Corp. Announces Private Placement for up to C$1,000,000
VANCOUVER, British Columbia, March 14, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | FRA: Q3J) (the " Company ”) is pleased to announce a non-brokered private placement for gross proceeds ...
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent ...
Korro Bio’s treatment of alpha-1 antitrypsin deficiency gets orphan designation
Korro Bio’s (KRRO) treatment of alpha-1 antitrypsin deficiency received FDA orphan designation, according to a post on the agency’s stie.Light ...
Dealbreaker on MSN5d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
TMCnet18d
Korro to Present at the TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...
Morningstar18d
Korro to Present at the TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based ...